

Proprietary Technology

The eLab system utilizes a proprietary nano-biosensor to generate multiple electrochemical assay results from a single patient sample. Specificity is generated by functionalizing each of the electrodes on the sensor for particular biomarkers. The sensor is incorporated into a single-use consumable microfluidics cartridge that processes the biological sample and reports its results through the handheld eLab instrument. Nanōmix has over 20 issued patents protecting its intellectual property.


A wide variety of biomolecules with varying chemistries can be tested on a single device in one operation

The electrochemical detection system eliminates the need for ongoing calibration and maintenance commonly associated with optical systems

Wireless connectivity provides for flexible transmission of patient results to other devices for data sharing, management, and EMR integration.

Central Laboratory Performance


Procalcitonin (PCT)



Performance of the eLab system is strongly correlated with the performance of central laboratory analyzers.

Testing of PCT clinical samples showed correlation of 94%+.

Cardiac Troponin (cTnI)



Testing of cTnI clinical samples showed a correlation of 96%+.

Central laboratory assay turn-around-times average 1.5 hours. Nanomix assays can be run on whole blood at the bedside or prior to hospital arrival and generate results in 10 minutes.

Corporate Partners

Nanōmix has formed a strategic partnership with the leader in the EMS space who will lead worldwide sales into the pre-hospital market. A recent equity investment and business collaboration with a Hong Kong life science group accelerates our entry to China and expands our product reach to Veterinary markets.

Team

Nanōmix's seasoned leadership team has the requisite experience for success. The team has backgrounds that include technology, microfluidics, assay development, software, manufacturing operations, clinical development and sales and marketing.

